Product Name

  • Name

    KANAMYCIN

  • EINECS 200-411-7
  • CAS No. 59-01-8
  • Article Data14
  • CAS DataBase
  • Density 1.62g/cm3
  • Solubility
  • Melting Point
  • Formula C18H36 N4 O11
  • Boiling Point 809.5°Cat760mmHg
  • Molecular Weight 484.504
  • Flash Point 443.4°C
  • Transport Information
  • Appearance
  • Safety Poison by intravenous and intramuscular routes. Moderately toxic by ingestion, intraperitoneal, and subcutaneous routes. An experimental teratogen. Experimental reproductive effects. Mutation data reported. When heated to decomposition it emits toxic fumes of NOx.
  • Risk Codes
  • Molecular Structure Molecular Structure of 59-01-8 (KANAMYCIN)
  • Hazard Symbols
  • Synonyms KanamycinA (7CI);4,6-Diamino-2-hydroxy-1,3-cyclohexane 3,6'-diamino-3,6'-dideoxydi-a-D-glucoside;KM;Kanacin;Kanamycin;
  • PSA 282.61000
  • LogP -4.49020

Synthetic route

Kanamycin A sulfate
3847-27-6, 25389-94-0, 64013-70-3, 81129-79-5, 84278-20-6, 94108-19-7, 94237-36-2

Kanamycin A sulfate

kanamycin A
59-01-8

kanamycin A

Conditions
ConditionsYield
With Amberlite IRA-400-OH In water91%
With Amberlite IRA-400 -OH In water
With Amberlite-IRA 400 (OH-)
C34H46N4O16

C34H46N4O16

A

kanamycin A
59-01-8

kanamycin A

B

1-deamino-1-dehydro-1-hydroxyiminokanamycin A

1-deamino-1-dehydro-1-hydroxyiminokanamycin A

Conditions
ConditionsYield
With hydrogen; acetic acid; palladium In water under 760 Torr; for 2h; Ambient temperature;A 4.7%
B 83%
6'-N-hydroxykanamicyn A (sulfate)
98084-09-4

6'-N-hydroxykanamicyn A (sulfate)

kanamycin A
59-01-8

kanamycin A

Conditions
ConditionsYield
With hydrogenchloride; hydrogen; platinum(IV) oxide In water under 2660 Torr; for 2h; Ambient temperature; Yield given;
di-tert-butyl ((1S,3R,4S,5R,6R)-4-(((2S,3R,4S,5S,6R)-4-((tert-butoxycarbonyl)amino)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-6-(((2R,3R,4S,5S,6R)-6-(((tert-butoxycarbonyl)amino)methyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)-5-hydroxycyclohexane-1,3-diyl)dicarbamate
80860-34-0

di-tert-butyl ((1S,3R,4S,5R,6R)-4-(((2S,3R,4S,5S,6R)-4-((tert-butoxycarbonyl)amino)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-6-(((2R,3R,4S,5S,6R)-6-(((tert-butoxycarbonyl)amino)methyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)-5-hydroxycyclohexane-1,3-diyl)dicarbamate

kanamycin A
59-01-8

kanamycin A

Conditions
ConditionsYield
tetrafluoroboric acid at 20℃; for 0.1h;
1-deamino-1-dehydro-1-hydroxyiminokanamycin A

1-deamino-1-dehydro-1-hydroxyiminokanamycin A

A

1-epi-kanamycin A
81076-65-5

1-epi-kanamycin A

B

kanamycin A
59-01-8

kanamycin A

Conditions
ConditionsYield
With ammonium hydroxide; hydrogen; nickel under 2280 Torr; for 5h; Ambient temperature;
3,6'-bis(N-benzyloxycarbonyl)-3"-N-(trifluoroacetyl)kanamycin A
74256-73-8

3,6'-bis(N-benzyloxycarbonyl)-3"-N-(trifluoroacetyl)kanamycin A

kanamycin A
59-01-8

kanamycin A

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 86 percent / sodium tungstate dihydrate, aq. H2O2 / various solvent(s) / Ambient temperature
2: aq. NH4OH / various solvent(s) / Ambient temperature
3: 4.7 percent / H2, AcOH / Pd black / H2O; various solvent(s) / 2 h / 760 Torr / Ambient temperature
View Scheme
Multi-step reaction with 4 steps
1: 86 percent / sodium tungstate dihydrate, aq. H2O2 / various solvent(s) / Ambient temperature
2: aq. NH4OH / various solvent(s) / Ambient temperature
3: 83 percent / H2, AcOH / Pd black / H2O; various solvent(s) / 2 h / 760 Torr / Ambient temperature
4: H2, aq. NH4OH / Raney Ni / 5 h / 2280 Torr / Ambient temperature
View Scheme
C34H46N4O16

C34H46N4O16

kanamycin A
59-01-8

kanamycin A

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 83 percent / H2, AcOH / Pd black / H2O; various solvent(s) / 2 h / 760 Torr / Ambient temperature
2: H2, aq. NH4OH / Raney Ni / 5 h / 2280 Torr / Ambient temperature
View Scheme
3,6'-bis(N-benzyloxycarbonyl)-1-deamino-1-dehydro-1-hydroxyimino-3"-N-(trifluoroacetyl)kanamycin A

3,6'-bis(N-benzyloxycarbonyl)-1-deamino-1-dehydro-1-hydroxyimino-3"-N-(trifluoroacetyl)kanamycin A

kanamycin A
59-01-8

kanamycin A

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: aq. NH4OH / various solvent(s) / Ambient temperature
2: 4.7 percent / H2, AcOH / Pd black / H2O; various solvent(s) / 2 h / 760 Torr / Ambient temperature
View Scheme
Multi-step reaction with 3 steps
1: aq. NH4OH / various solvent(s) / Ambient temperature
2: 83 percent / H2, AcOH / Pd black / H2O; various solvent(s) / 2 h / 760 Torr / Ambient temperature
3: H2, aq. NH4OH / Raney Ni / 5 h / 2280 Torr / Ambient temperature
View Scheme
2'-oxokanamycin

2'-oxokanamycin

kanamycin A
59-01-8

kanamycin A

Conditions
ConditionsYield
With His-tagged NADPH-dependent reductase; potassium chloride; glycerol; NADPH at 28℃; pH=7.5; Tris-HCl buffer; Enzymatic reaction; stereoselective reaction;
C22H43N5O13*2H2O4S

C22H43N5O13*2H2O4S

kanamycin A
59-01-8

kanamycin A

Conditions
ConditionsYield
With sodium hydroxide In water at 20℃; for 20h; Reagent/catalyst; Solvent; Temperature;
4‐nitrophenyl N‐benzylcarbamate
124068-97-9

4‐nitrophenyl N‐benzylcarbamate

kanamycin A
59-01-8

kanamycin A

1-benzyl-3-{5-(3-benzyl-ureido)-4-[4-(3-benzyl-ureido)-3,5-dihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy]-2-[6-(3-benzyl-ureidomethyl)-3,4,5-trihydroxy-tetrahydro-pyran-2-yloxy]-3-hydroxy-cyclohexyl}-urea
1054616-53-3

1-benzyl-3-{5-(3-benzyl-ureido)-4-[4-(3-benzyl-ureido)-3,5-dihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy]-2-[6-(3-benzyl-ureidomethyl)-3,4,5-trihydroxy-tetrahydro-pyran-2-yloxy]-3-hydroxy-cyclohexyl}-urea

Conditions
ConditionsYield
With triethylamine In 1,4-dioxane; water at 20℃; for 3h;93%
kanamycin A
59-01-8

kanamycin A

1,3-di(tert-butyloxycarbonyl)-2-(trifluoromethylsulfonyl)guanidine
207857-15-6

1,3-di(tert-butyloxycarbonyl)-2-(trifluoromethylsulfonyl)guanidine

guanidinoboc8-kanamycin

guanidinoboc8-kanamycin

Conditions
ConditionsYield
With triethylamine In 1,4-dioxane; water at 20℃;91%
kanamycin A
59-01-8

kanamycin A

1,3-di(tert-butyloxycarbonyl)-2-(trifluoromethylsulfonyl)guanidine
207857-15-6

1,3-di(tert-butyloxycarbonyl)-2-(trifluoromethylsulfonyl)guanidine

C62H108N12O27
290360-47-3

C62H108N12O27

Conditions
ConditionsYield
With triethylamine In 1,4-dioxane; water at 20℃; for 72h;91%
di-tert-butyl dicarbonate
24424-99-5

di-tert-butyl dicarbonate

kanamycin A
59-01-8

kanamycin A

di-tert-butyl ((1S,3R,4S,5R,6R)-4-(((2S,3R,4S,5S,6R)-4-((tert-butoxycarbonyl)amino)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-6-(((2R,3R,4S,5S,6R)-6-(((tert-butoxycarbonyl)amino)methyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)-5-hydroxycyclohexane-1,3-diyl)dicarbamate
80860-34-0

di-tert-butyl ((1S,3R,4S,5R,6R)-4-(((2S,3R,4S,5S,6R)-4-((tert-butoxycarbonyl)amino)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-6-(((2R,3R,4S,5S,6R)-6-(((tert-butoxycarbonyl)amino)methyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)-5-hydroxycyclohexane-1,3-diyl)dicarbamate

Conditions
ConditionsYield
In water; N,N-dimethyl-formamide at 60℃; for 5h;91%
With sodium carbonate In methanol; water at 20℃; for 4h;90%
In water; dimethyl sulfoxide at 70℃; for 20h;84%
In water; dimethyl sulfoxide at 70℃; for 20h;84%
With triethylamine In water; N,N-dimethyl-formamide at 60℃; for 6h; Inert atmosphere;76%
2,2-dimethylpropanoic anhydride
1538-75-6

2,2-dimethylpropanoic anhydride

kanamycin A
59-01-8

kanamycin A

di-tert-butyl ((1S,3R,4S,5R,6R)-4-(((2S,3R,4S,5S,6R)-4-((tert-butoxycarbonyl)amino)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-6-(((2R,3R,4S,5S,6R)-6-(((tert-butoxycarbonyl)amino)methyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)-5-hydroxycyclohexane-1,3-diyl)dicarbamate
80860-34-0

di-tert-butyl ((1S,3R,4S,5R,6R)-4-(((2S,3R,4S,5S,6R)-4-((tert-butoxycarbonyl)amino)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-6-(((2R,3R,4S,5S,6R)-6-(((tert-butoxycarbonyl)amino)methyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)-5-hydroxycyclohexane-1,3-diyl)dicarbamate

Conditions
ConditionsYield
In methanol; water90%
benzyl chloroformate
501-53-1

benzyl chloroformate

kanamycin A
59-01-8

kanamycin A

1,3,6',2''-tetra-N-benzyloxycarbonyl-kanamycin A
5605-66-3

1,3,6',2''-tetra-N-benzyloxycarbonyl-kanamycin A

Conditions
ConditionsYield
With sodium carbonate In acetone at 20℃; for 18h;84%
With sodium carbonate In water Yield given;
C16H20N2O4S2

C16H20N2O4S2

kanamycin A
59-01-8

kanamycin A

amikacin
37517-28-5

amikacin

Conditions
ConditionsYield
Stage #1: kanamycin A With chloro-trimethyl-silane; 1,1,1,3,3,3-hexamethyl-disilazane In acetonitrile Reflux;
Stage #2: C16H20N2O4S2 In acetone; acetonitrile at 0 - 5℃; for 1h;
Stage #3: With hydrogenchloride In water; acetone; acetonitrile for 1h; pH=2 - 3; Solvent; Reagent/catalyst; Temperature;		83%
C31H30N3O12P
1608113-35-4

C31H30N3O12P

kanamycin A
59-01-8

kanamycin A

5'-O-(dibenzylphosphate)-3'-O-(kanamycin A carbamate)thymidine

5'-O-(dibenzylphosphate)-3'-O-(kanamycin A carbamate)thymidine

Conditions
ConditionsYield
With triethylamine In 1,4-dioxane; water at 0 - 20℃; for 16h;82%
N-(phenylacetyl)oxysuccinimide
23776-85-4

N-(phenylacetyl)oxysuccinimide

kanamycin A
59-01-8

kanamycin A

tetra N-phenylacetyl-kanamycin A
1352640-83-5

tetra N-phenylacetyl-kanamycin A

Conditions
ConditionsYield
With sodium hydrogencarbonate In water; N,N-dimethyl-formamide at 20℃;81%
N,N'-bis( tert-butoxycarbonyl)-1H-pyrazole-1-carboxamidine
152120-54-2, 862686-58-6, 1143572-00-2

N,N'-bis( tert-butoxycarbonyl)-1H-pyrazole-1-carboxamidine

kanamycin A
59-01-8

kanamycin A

C29H54N6O15

C29H54N6O15

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In 1,4-dioxane; water at 20℃; for 5h;78%
5-benzoyl-3-(cyclopent-1-en-1-yl)-5-phenyl-1,5-dihydro-4H-pyrazol-4-one

5-benzoyl-3-(cyclopent-1-en-1-yl)-5-phenyl-1,5-dihydro-4H-pyrazol-4-one

kanamycin A
59-01-8

kanamycin A

C25H40N4O12

C25H40N4O12

Conditions
ConditionsYield
In dimethyl sulfoxide at 50℃; for 72h;77%
kanamycin A
59-01-8

kanamycin A

Boc-S

Boc-S

di-tert-butyl ((1S,3R,4S,5R,6R)-4-(((2S,3R,4S,5S,6R)-4-((tert-butoxycarbonyl)amino)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-6-(((2R,3R,4S,5S,6R)-6-(((tert-butoxycarbonyl)amino)methyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)-5-hydroxycyclohexane-1,3-diyl)dicarbamate
80860-34-0

di-tert-butyl ((1S,3R,4S,5R,6R)-4-(((2S,3R,4S,5S,6R)-4-((tert-butoxycarbonyl)amino)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-6-(((2R,3R,4S,5S,6R)-6-(((tert-butoxycarbonyl)amino)methyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)-5-hydroxycyclohexane-1,3-diyl)dicarbamate

Conditions
ConditionsYield
With triethylamine In 1,4-dioxane; water for 24h; Ambient temperature;75%
kanamycin A
59-01-8

kanamycin A

N-(t-butoxycarbonyloxy)-5-norbornene-endo-2,3-dicarboximide

N-(t-butoxycarbonyloxy)-5-norbornene-endo-2,3-dicarboximide

6'-N-(tert-Butoxycarbonyl)kanamycin A

6'-N-(tert-Butoxycarbonyl)kanamycin A

Conditions
ConditionsYield
In dimethyl sulfoxide Ambient temperature;70%
benzoyl chloride
98-88-4

benzoyl chloride

kanamycin A
59-01-8

kanamycin A

tetra N-benzoyl-kanamycin A

tetra N-benzoyl-kanamycin A

Conditions
ConditionsYield
With sodium carbonate In methanol; water at 0℃;68%
N-(Benzyloxycarbonyloxy)succinimide
13139-17-8

N-(Benzyloxycarbonyloxy)succinimide

kanamycin A
59-01-8

kanamycin A

1,3,6',2''-tetra-N-benzyloxycarbonyl-kanamycin A
5605-66-3

1,3,6',2''-tetra-N-benzyloxycarbonyl-kanamycin A

Conditions
ConditionsYield
With sodium hydrogencarbonate In water; N,N-dimethyl-formamide at 20℃;66%
p-methoxybenzyl-S-(4,6-dimethylpyrimidine-2-yl)thiocarbonate
93801-72-0

p-methoxybenzyl-S-(4,6-dimethylpyrimidine-2-yl)thiocarbonate

kanamycin A
59-01-8

kanamycin A

3,6'-di-N-p-methoxybenzyloxycarbonyl kanamycin A
93801-63-9

3,6'-di-N-p-methoxybenzyloxycarbonyl kanamycin A

Conditions
ConditionsYield
With nickel diacetate In dimethyl sulfoxide for 0.5h;65%
azidoacetic acid succinimidyl ester

azidoacetic acid succinimidyl ester

kanamycin A
59-01-8

kanamycin A

C20H37N7O12
1220984-53-1

C20H37N7O12

Conditions
ConditionsYield
With potassium carbonate In methanol; water for 20h;55%
N-(Benzyloxycarbonyloxy)succinimide
13139-17-8

N-(Benzyloxycarbonyloxy)succinimide

kanamycin A
59-01-8

kanamycin A

3,6'-bis-N-benzyloxycarbonylkanamycin A
66567-24-6

3,6'-bis-N-benzyloxycarbonylkanamycin A

Conditions
ConditionsYield
Stage #1: kanamycin A With zinc diacetate In dimethyl sulfoxide Inert atmosphere;
Stage #2: N-(Benzyloxycarbonyloxy)succinimide In dimethyl sulfoxide Inert atmosphere;		50%
With zinc diacetate In dimethyl sulfoxide Inert atmosphere;50%
Stage #1: kanamycin A With zinc diacetate In dimethyl sulfoxide at 20℃; for 12h;
Stage #2: N-(Benzyloxycarbonyloxy)succinimide In dimethyl sulfoxide for 2h;
kanamycin A
59-01-8

kanamycin A

Kanamycin A-3'-phosphate
17029-36-6

Kanamycin A-3'-phosphate

Conditions
ConditionsYield
With Tmed buffer; magnesium acetate In water for 12h; aminoglycoside phosphotransferase;44%
acetone O-<(vinyloxy)carbonyl>oxime
139705-38-7

acetone O-<(vinyloxy)carbonyl>oxime

kanamycin A
59-01-8

kanamycin A

{4-(3,5-dihydroxy-6-hydroxymethyl-4-vinyloxycarbonylamino-tetrahydro-pyran-2-yloxy)-3-hydroxy-2-[3,4,5-trihydroxy-6-(vinyloxycarbonylamino-methyl)-tetrahydro-pyran-2-yloxy]-5-vinyloxycarbonylamino-cyclohexyl}-carbamic acid vinyl ester
791064-46-5

{4-(3,5-dihydroxy-6-hydroxymethyl-4-vinyloxycarbonylamino-tetrahydro-pyran-2-yloxy)-3-hydroxy-2-[3,4,5-trihydroxy-6-(vinyloxycarbonylamino-methyl)-tetrahydro-pyran-2-yloxy]-5-vinyloxycarbonylamino-cyclohexyl}-carbamic acid vinyl ester

Conditions
ConditionsYield
With sodium hydroxide In phosphate buffer at 0℃; for 5h; pH=8.0;37%
2,4,6-trinitrobenzensulfonate
2508-19-2

2,4,6-trinitrobenzensulfonate

kanamycin A
59-01-8

kanamycin A

tetra N-(2,4,6-trinitrophenyl)kanamycin A

tetra N-(2,4,6-trinitrophenyl)kanamycin A

Conditions
ConditionsYield
With pyridine In water at 70℃; for 0.333333h;29%
N-[(S)-4-benzyloxycarbonylamino-2-hydroxy-butyryloxy]succinimide
40371-52-6

N-[(S)-4-benzyloxycarbonylamino-2-hydroxy-butyryloxy]succinimide

kanamycin A
59-01-8

kanamycin A

A

C30H49N5O15

C30H49N5O15

B

C42H62N6O19

C42H62N6O19

Conditions
ConditionsYield
Stage #1: kanamycin A With zinc diacetate In water; N,N-dimethyl-formamide at 20℃; for 16h;
Stage #2: N-[(S)-4-benzyloxycarbonylamino-2-hydroxy-butyryloxy]succinimide In water; N,N-dimethyl-formamide for 24h;		A 12%
B 16%
...Expand
acetic anhydride
108-24-7

acetic anhydride

kanamycin A
59-01-8

kanamycin A

tetra-N-hepta-O-acetylkanamycin A
144727-29-7

tetra-N-hepta-O-acetylkanamycin A

Conditions
ConditionsYield
With pyridine
kanamycin A
59-01-8

kanamycin A

ATP
56-65-5

ATP

C28H48N9O17P

C28H48N9O17P

Conditions
ConditionsYield
at 37℃; aminoglycoside-4'-nucleotidyltransferaze of Bacillus brevis, MgCl2, potassium phosphate buffer (pH 6.0);
kanamycin A
59-01-8

kanamycin A

C18H32(2)H4N4O11*4ClH

C18H32(2)H4N4O11*4ClH

Conditions
ConditionsYield
With diclazuril In water-d2

Kanamycin Chemical Properties

Product Name: Kanamycin (CAS NO.59-01-8)


Molecular Formula: C18H36N4O11
Molecular Weight: 484.5g/mol
Mol File: 59-01-8.mol
Einecs: 200-411-7
Boiling point: 809.5 °C at 760 mmHg
Storage Temperature: 2-8°C
Flash Point: 443.4 °C
Density: 1.62 g/cm3
Surface Tension: 104.4 dyne/cm
Enthalpy of Vaporization: 134 kJ/mol
Vapour Pressure: 2.47E-30 mmHg at 25°C
XLogP3-AA: -6.9
H-Bond Donor: 11
H-Bond Acceptor: 15

Kanamycin Uses

 Kanamycin (CAS NO.59-01-8) is for the production of sulfuric acid amikacin, kanamycin monosulfate, and pairs of kanamycin sulfate intermediates.
It is used in molecular biology as a selective agent most commonly to isolate bacteria (e.g., E. coli) which have taken up genes (e.g., of plasmids) coupled to a gene coding for kanamycin resistance (primarily Neomycin phosphotransferase II [NPT II/Neo]). Bacteria that have been transformed with a plasmid containing the kanamycin resistance gene are plated on kanamycin (50-100mg/L) containing agar plates or are grown in media containing kanamycin (50-100mg/L). Only the bacteria that have successfully taken up the kanamycin resistance gene become resistant and will grow under these conditions. As a powder kanamycin is white to off-white and is soluble in water (50mg/ml).
At least one such gene, Atwbc19 is native to a plant species, of comparatively large size and its coded protein acts in a manner which decreases the possibility of Horizontal Gene Transfer from the plant to bacteria; it may be incapable of giving resistance to kanamycin to bacteria even if gene transfer occurs.

Kanamycin Toxicity Data With Reference

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
guinea pig LD50 intraperitoneal 1385mg/kg (1385mg/kg)   Antibiotiki. Vol. 19, Pg. 552, 1974.
human TDLo unreported 843mg/kg/17W- (843mg/kg) SENSE ORGANS AND SPECIAL SENSES: CHANGE IN ACUITY: EAR

SENSE ORGANS AND SPECIAL SENSES: TINNITUS: EAR

KIDNEY, URETER, AND BLADDER: OTHER CHANGES IN URINE COMPOSITION		 American Review of Respiratory Disease. Vol. 82, Pg. 23, 1960.
mouse LD50 intracrebral 33750ug/kg (33.75mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

CARDIAC: OTHER CHANGES

LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION		 Chemotherapy Vol. 17, Pg. 1664, 1969.
mouse LD50 intramuscular 54mg/kg (54mg/kg)   Bollettino Chimico Farmaceutico. Vol. 98, Pg. 224, 1959.
mouse LD50 intraperitoneal 794mg/kg (794mg/kg)   Chemotherapy Vol. 16, Pg. 371, 1971.
mouse LD50 intravenous 115mg/kg (115mg/kg)   Minerva Farmaceutica. Vol. 11, Pg. 108, 1962.
mouse LD50 oral 20700ug/kg (20.7mg/kg)   Antibiotiki. Vol. 19, Pg. 552, 1974.
mouse LD50 subcutaneous 1350mg/kg (1350mg/kg)   Antimicrobial Agents and Chemotherapy Vol. -, Pg. 341, 1967.
rabbit LD50 intravenous 150mg/kg (150mg/kg)   "Antibiotics: Origin, Nature, and Properties," Korzyoski, T., et al., eds., Washington, DC, American Soc. for Microbiology, 1978Vol. 1, Pg. 690, 1978.
rat LD50 intramuscular > 1014mg/kg (1014mg/kg) BEHAVIORAL: ATAXIA

LUNGS, THORAX, OR RESPIRATION: CYANOSIS

LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES		 Chemotherapy Vol. 29(Suppl,
rat LD50 intraperitoneal 1515mg/kg (1515mg/kg)   Antibiotiki. Vol. 19, Pg. 552, 1974.
rat LD50 intravenous 437mg/kg (437mg/kg)   Chemotherapy Vol. 29(Suppl,
rat LD50 oral > 10gm/kg (10000mg/kg)   Chemotherapy Vol. 29(Suppl,
rat LD50 subcutaneous 4070mg/kg (4070mg/kg)   Archives Internationales de Pharmacodynamie et de Therapie. Vol. 176, Pg. 59, 1968.

Kanamycin Consensus Reports

Reported in EPA TSCA Inventory. EPA Genetic Toxicology Program.

Kanamycin Safety Profile

Poison by intravenous and intramuscular routes. Moderately toxic by ingestion, intraperitoneal, and subcutaneous routes. An experimental teratogen. Experimental reproductive effects. Mutation data reported. When heated to decomposition it emits toxic fumes of NOx.

Kanamycin Specification

 Kanamycin ,its CAS NO. is 59-01-8,the synonyms is Kanamycin a ; Kanamycin base ; 2-Deoxy-y-alpha-d-glucopyranosyl- ; 4,6-Diamino-2-hydroxy-1,3-cyclohexane3,6'diamino-3,6'-dideoxydi-alpha-d-gluc ; 4,6-Diamino-2-hydroxy-1,3-cyclohexane3,6'diamino-3,6'-dideoxydi-alpha-d-glucos ; D-deoxydi ; D-streptamine,o-3-amino-3-deoxy-alpha-d-glucopyranosyl-(1.fwdarw.6)-o-6-amin .

Related Products

Hot Products

Post buying leads

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View